Open-label, Phase 1 Study of haNK™ for Infusion in Subjects With Metastatic or Locally Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 07 Nov 2018
At a glance
- Drugs CD16 and interleukin 2 expressing natural killer cells-NantKwest (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Acronyms QUILT-3.028
- Sponsors NantKwest
- 07 Nov 2018 Results published in the Media Release
- 02 Oct 2017 According to a NantKwest media release, first patient has been treated.
- 23 Aug 2017 Status changed from not yet recruiting to recruiting.